ENANTA PHARMACEUTICALS INC (ENTA) Stock Analyst Ratings
USA - NASDAQ:ENTA - US29251M1062 - Common Stock
11.93 USD
-0.11 (-0.91%)
11.93 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 83% to ENTA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 19.53. This target is 63.67% above the current price.
ENTA was analyzed by 13 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about ENTA.
In the previous month the buy percentage consensus was at a similar level.
ENTA was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-30 | WestPark Capital | Maintains | Buy -> Buy |
| 2025-09-15 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-09-02 | WestPark Capital | Initiate | Buy |
| 2025-08-12 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-06-03 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-02-11 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-26 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-11-26 | Baird | Maintains | Outperform -> Outperform |
| 2024-10-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-09 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-09-27 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-08-06 | JP Morgan | Maintains | Underweight -> Underweight |
| 2024-08-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-07 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-05-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-08 | JP Morgan | Maintains | Underweight -> Underweight |
| 2023-11-22 | Oppenheimer | Maintains | Perform -> Perform |
| 2023-11-21 | JMP Securities | Maintains | Outperform -> Outperform |
| 2023-11-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-10-23 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-10-02 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2023-09-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-09 | Oppenheimer | Maintains | Perform -> Perform |
| 2023-08-08 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2023-08-08 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2023-08-08 | Jefferies | Downgrade | Buy -> Hold |
| 2023-08-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-11 | Oppenheimer | Reiterate | Perform -> Perform |
ENANTA PHARMACEUTICALS INC / ENTA FAQ
What is the price target for ENTA stock?
13 analysts have analysed ENTA and the average price target is 19.53 USD. This implies a price increase of 63.67% is expected in the next year compared to the current price of 11.93.
Can you provide the consensus rating for ENANTA PHARMACEUTICALS INC stock?
The consensus rating for ENANTA PHARMACEUTICALS INC (ENTA) is 83.0769 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for ENANTA PHARMACEUTICALS INC stock?
The number of analysts covering ENANTA PHARMACEUTICALS INC (ENTA) is 13.